Abstract
RATIONALE: The reduction in upper airway muscle activity from wakefulness to sleep plays a key role in the development of obstructive sleep apnea. Potassium (K(+)) channels have been recently identified as the downstream mechanisms through which hypoglossal motoneuron membrane excitability is reduced both in non-rapid eye movement (NREM) sleep and REM sleep. In animal models, the administration of 4-aminopyridine (4-AP), a voltage-gated K(+) channel blocker, increased genioglossus activity during wakefulness and across all sleep stages. OBJECTIVES: We tested the hypothesis that administration of a single dose of 4-AP 10 mg extended release would increase genioglossus activity (electromyography of the genioglossus muscle [EMG(GG)]) during wakefulness and sleep, and thereby decrease pharyngeal collapsibility. METHODS: We performed a randomized controlled crossover proof-of-concept trial in 10 healthy participants. Participants received active treatment or placebo in randomized order 3 hours before bedtime in the physiology laboratory. RESULTS: EMG(GG) during wakefulness and NREM sleep and upper airway collapsibility measured during NREM sleep were unchanged between placebo and 4-AP nights. Tonic but not phasic EMG(GG) during REM sleep was higher on the 4-AP night when measured as a percentage of maximal voluntary activation (median [interquartile range] 0.3 [0.5] on placebo vs. 0.8 [1.9] %(max) on 4 AP; P = 0.04), but not when measured in μV or as a percentage of wakefulness value. CONCLUSIONS: A single dose of 4-AP 10 mg extended release showed only a small increase in tonic EMG(GG) during REM sleep in this group of healthy subjects. We speculate that a higher dose of 4-AP may further increase EMG(GG). However, given the potentially severe, dose-related adverse effects of this drug, including seizures, the administration of 4-AP does not appear to be an effective strategy to increase genioglossus activity during sleep in humans. Clinical Trial registered with clinicaltrials.gov (NCT02656160).